About: Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety
Creator	Astier, Alain Astier, J-F Bardin, Christophe Baudouin, A Baudouin, Amandine Cazin, Jean-Louis Chevrier, Régine Daouphars, Mikaël Daouphars, R Madelaine, Isabelle Pourroy, Bertrand Ranchon, A Ranchon, Florence Rioufol, C Rioufol, Catherine Rioufol@chu-Lyon, Catherine Slimano, F Slimano, Florian Thomas-Schoemann, Audrey Toulemonde-Deldicque, Anne Tournamille, Jean-François Zerbit, Jérémie
source	Elsevier; Medline; PMC; WHO
abstract	Abstract The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.
has issue date	2020-06-23(xsd:dateTime)
bibo:doi	10.1016/j.ctrv.2020.102063
bibo:pmid	32623296
has license	els-covid
sha1sum (hex)	e1ad1374aa168ec27f0e5979a17e8b675afebe21
schema:url	https://doi.org/10.1016/j.ctrv.2020.102063
resource representing a document's title	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety
has PubMed Central identifier	PMC7308737
has PubMed identifier	32623296
schema:publication	Cancer Treat Rev
resource representing a document's body	covid:e1ad1374aa168ec27f0e5979a17e8b675afebe21#body_text
is schema:about of	named entity 'susceptibility' named entity 'severe' named entity 'oncologists' named entity 'pandemic' named entity 'rethink' named entity 'COVID-19' named entity 'trametinib' named entity 'immune function' named entity 'ECG monitoring' named entity 'Antidepressants' named entity 'ritonavir' named entity 'pharmacy' named entity 'lopinavir' named entity 'lenalidomide' named entity 'autoimmune hepatitis' named entity 'cyclosporine' named entity 'limit contact' named entity 'adverse effects' named entity 'toxicity' named entity 'COVID-19 infection' named entity 'antidepressant' named entity 'cytokine storm' named entity 'COVID' named entity 'lopinavir' named entity 'Cardiotoxicity' named entity '1.2' named entity 'SARS-CoV-2 virus' named entity 'Hydroxychloroquine' named entity 'SARS-CoV' named entity 'protein' named entity 'citalopram' named entity 'nivolumab' named entity 'hydroxychloroquine' named entity 'general population' named entity 'infection' named entity 'lung cancer' named entity 'thalidomide' named entity 'drug-related' named entity 'antineoplastics' named entity 'orphan drug status' named entity 'infection' named entity 'based on evidence' named entity 'COVID-19' named entity 'comorbidities' named entity 'enzalutamide' named entity 'cabozantinib' named entity 'Lopinavir and ritonavir' named entity 'hematologic cancer' named entity 'QT prolongation' named entity 'multivariate analysis' named entity 'glomerular filtration rate' named entity 'hypokalemia' named entity 'immune checkpoint inhibitors' named entity 'malignancies' named entity 'trastuzumab' named entity 'pharmacy' named entity 'chronic kidney failure' named entity 'pharmacy' named entity 'corticosteroids' named entity 'case fatality rate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software